Reasons for canakinumab initiation among patients with periodic fever syndromes: a retrospective medical chart review from the United States

Although canakinumab has demonstrated efficacy in multiple trials in patients with periodic fever syndromes (PFS), the evidence on initiation of canakinumab among PFS patients in real world setting is not well understood. We aimed to characterize the reasons for canakinumab initiation among patients...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric Rheumatology 2021-09, Vol.19 (1), p.143-143, Article 143
Main Authors: Hur, Peter, Lomax, Kathleen G, Ionescu-Ittu, Raluca, Manceur, Ameur M, Xie, Jipan, Cammarota, Jordan, Gautam, Raju, Sanghera, Navneet, Kim, Nina, Grom, Alexei A
Format: Article
Language:English
Subjects:
Access to information
Adolescent
Adult
Adults
Age
Amyloidosis
Antibodies, Monoclonal, Humanized - therapeutic use
Canakinumab
Child
Child, Preschool
Clinical medicine
Colchicine
Cryopyrin-associated periodic fever syndrome
Cryopyrin-Associated Periodic Syndromes - drug therapy
Data collection
Dermatology
Disease
Drug Prescriptions
Familial Mediterranean fever
Familial Mediterranean Fever - drug therapy
Female
Fever
Fever - drug therapy
Genetic aspects
Hereditary Autoinflammatory Diseases - drug therapy
Humans
Hyperimmunoglobulin D syndrome
Immunology
Immunotherapy
Inflammatory diseases
Male
Mevalonate kinase deficiency
Mevalonate Kinase Deficiency - drug therapy
Monoclonal antibodies
Patients
Pediatrics
Physicians
Practice Patterns, Physicians
Real world
Retrospective Studies
Rheumatology
Rilonacept
Tumor necrosis factor
United States
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Although canakinumab has demonstrated efficacy in multiple trials in patients with periodic fever syndromes (PFS), the evidence on initiation of canakinumab among PFS patients in real world setting is not well understood. We aimed to characterize the reasons for canakinumab initiation among patients with PFS, specifically, cryopyrin-associated periodic syndrome (CAPS), hyperimmunoglobulin D syndrome/mevalonate kinase deficiency (HIDS/MKD), TNF receptor-associated periodic syndrome (TRAPS) and familial Mediterranean fever (FMF). Physicians retrospectively reviewed the medical charts of PFS patients prescribed canakinumab between 2016 and 2018. Information collected included patient clinical characteristics, reasons for previous treatment discontinuation and canakinumab initiation. The results were summarized for overall patients, and by children (
ISSN:1546-0096
1546-0096
DOI:10.1186/s12969-021-00605-2